文献速递腹部MR

LI-RADS v2018新策略提高细胞外对比剂增强MRI对≤3.0 cm小肝细胞癌的敏感性

New strategy of LI-RADS v2018 to improve the sensitivity for small hepatocellular carcinoma ≤ 3.0 cm on extracellular-contrast enhanced MRI.
PubMed 文献 · Eur J Radiol · 2024-11-09

本研究纳入五个独立中心984例高危患者共1204个观察灶(其中997个≤30 mm),评估修改版LI-RADS对≤30 mm小肝细胞癌的诊断价值。修改版LI-RADS将无动脉期高强化(APHE)任何大小伴两个主要特征、非环状APHE伴一个主要特征(≥10 mm)或伴两个主要特征(<10 mm)纳入LR-5。修改版LI-RADS对小肝细胞癌的敏感性高于LI-RADS v2018(76.8~85.5% vs 73.7~75.9%,P<0.05),且以AFP≥200 ng/mL作为附加特征或替代阈值增长时敏感性进一步提高(82.1~90.1%),特异性相当。

要点

  • 修改版LI-RADS将无APHE任何大小伴两个主要特征、非环状APHE伴一个主要特征(≥10 mm)或伴两个主要特征(<10 mm)纳入LR-5。
  • 修改版LI-RADS对≤30 mm小肝细胞癌的敏感性为76.8~85.5%,高于LI-RADS v2018的73.7~75.9%。
  • 以AFP≥200 ng/mL作为附加特征或替代阈值增长时敏感性为82.1~90.1%,特异性与LI-RADS v2018相当。

核心结论

  • LI-RADS v2018新策略在细胞外对比剂增强MRI上诊断小肝细胞癌的敏感性显著高于LI-RADS v2018,特异性相当。

研究设计与样本

  • 多中心研究,纳入五个独立中心984例肝细胞癌高危患者共1204个观察灶(其中997个≤30 mm),均行细胞外对比剂增强MRI,盲法阅片者评估LI-RADS特征并按LI-RADS v2018、修改版LI-RADS和EASL分类。

诊断标准与关键数值

  • 修改版LR-5标准:无APHE任何大小伴两个主要特征,非环状APHE伴一个主要特征(≥10 mm)或伴两个主要特征(<10 mm)。
  • 修改版LI-RADS对小肝细胞癌的敏感性为76.8~85.5%,LI-RADS v2018为73.7~75.9%(P<0.05)。
  • 修改版LI-RADS以AFP≥200 ng/mL作为附加特征或替代阈值增长时敏感性为82.1~90.1%,高于LI-RADS v2018的73.7~75.9%、修改版LI-RADS的76.8~85.5%和EASL 2018版的73.3~74.7%(均P<0.05)。
  • 修改版LI-RADS与LI-RADS v2018、EASL 2018版的特异性相当(均P>0.05)。

临床应用与阅片要点

  • 动脉期高强化、廓清、强化包膜和五个高水平AFP值是小肝细胞癌的独立相关因素。
  • 修改版LI-RADS可提高≤30 mm小肝细胞癌的检出敏感性,且特异性与LI-RADS v2018相当。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

英文原文(摘要)· 点击展开

INTRODUCTION: We aimed to modify LI-RADS version 2018 to improve sensitivity and determine the value of the combination of high alpha-fetoprotein (AFP) levels for small HCC (sHCC, ≤ 30 mm) diagnosis.

METHODS: A total of 984 patients at high risk for HCC, with 1204 observations (including 997 small observations ≤ 30 mm), who underwent extracellular contrast-enhanced MRI were enrolled from five independent centers. Blinded readers evaluated the LI-RADS features and categorized each observation according to the LI-RADS v2018, modified LI-RADS and EASL. Odds ratios of LI-RADS major features (MFs) and several high AFP levels for sHCC diagnosis were analyzed using multivariable logistic regression. The modified LR-5 criteria was developed by including no APHE at any size with two MFs, and non-rim APHE with one MF (≥ 10 mm) or with two MFs (< 10 mm). The diagnostic performance of each version of the LR-5 was compared using generalized estimating equations.

RESULTS: APHE, washout, enhancing capsule and five high AFP levels were independently associated with sHCC. In three datasets, the modified LI-RADS had higher sensitivities for sHCC (76.8 ∼ 85.5 % vs. 73.7 ∼ 75.9 %, P < 0.05) to the LR-5 v2018. The modified LI-RADS with AFP ≥ 200 ng/mL as an additional feature or as an alternative to threshold growth provided higher sensitivities for sHCC than LI-RADS v2018 (82.1 ∼ 90.1 % vs. 73.7 ∼ 75.9 %, all P < 0.05), modified LI-RADS (82.1 ∼ 90.1 % vs. 76.8 ∼ 85.5 %, all P < 0.05) and EASL version 2018 (82.1 ∼ 90.1 % vs. 73.3 ∼ 74.7 %, all P < 0.05), with comparable specificities (all P > 0.05).

CONCLUSION: The new strategy of LI-RADS v2018 provides significantly higher sensitivity and comparable specificity than those of LI-RADS v2018 for sHCC diagnosis on ECA-MRI.

来源:Eur J Radiol,查看原文。版权归原作者所有。

引用

  1. Zhou J, Zhang Y, Zhang J, et al. New strategy of LI-RADS v2018 to improve the sensitivity for small hepatocellular carcinoma ≤ 3.0 cm on extracellular-contrast enhanced MRI. Eur J Radiol. 2024. PMID: 39547000. doi:10.1016/j.ejrad.2024.111830

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。